Kimberly J Lee

US Patent:

7807789, Oct 5, 2010

Filed:

Jun 21, 2007

Appl. No.:

11/821130

Inventors:

Ailan Guo - Burlington MA, US
Kimberly Lee - Seattle WA, US
Klarisa Rikova - Reading MA, US
Charles Farnsworth - Concord MA, US
Albrecht Moritz - Salem MA, US
Yu Li - Andover MA, US
Robert Polakiewicz - Lexington MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C12P 21/08
C07K 16/28

US Classification:

5303871, 5303881, 53038822, 5303891, 5303911, 5303913, 4241301, 4241411, 4241431, 4241781

Abstract:

The invention discloses 168 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of, and including, EGFR kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor/Scaffold proteins, Calcium-Binding Proteins, Cell Cycle Regulation proteins, Cytoskeletal proteins, DNA Binding and Replication Proteins, GTPase Activating proteins, Guanine Nucleotide Exchange Factor proteins, Lipid Kinases, Receptor Tyrosine Kinases, Receptor Tyrosine Kinase ligands, Protein Kinases, Receptor and Protein Phosphatases, Transcription Factor proteins, Tumor Suppressor proteins, and Vesicle proteins.

US Patent:

7888480, Feb 15, 2011

Filed:

Feb 29, 2008

Appl. No.:

12/074224

Inventors:

Roberto Polakiewicz - Lexington MA, US
Valerie Goss - Seabrook NH, US
Albrecht Moritz - Salem MA, US
Kimberly Lee - Seattle WA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C07K 16/00

US Classification:

5303879

Abstract:

The invention discloses nearly 288 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins.

US Patent:

7932044, Apr 26, 2011

Filed:

Jul 1, 2005

Appl. No.:

11/174051

Inventors:

Klarisa Rikova - Reading MA, US
Roberto Polakiewicz - Lexington MA, US
Ailan Guo - Burlington MA, US
Katherine Crosby - Middleton MA, US
Qingfu Zeng - Hamilton MA, US
Kimberly Lee - Boston MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

G01N 33/53
G01N 33/574
C12Q 1/68

US Classification:

435 71, 435 6, 435 723

Abstract:

The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFRα) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFRα is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFRα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor.

US Patent:

7935790, May 3, 2011

Filed:

Aug 11, 2006

Appl. No.:

11/503336

Inventors:

Albrecht Moritz - Salem MA, US
Roberto Polakiewicz - Lexington MA, US
John Edward Rush - Beverly MA, US
Kimberly Lee - Seattle WA, US

Assignee:

Cell Singaling Technology, Inc. - Danvers MA

International Classification:

C07K 16/00
C07K 16/18

US Classification:

5303871, 5303879

Abstract:

The invention discloses 95 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of the T-cell receptor, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor/Scaffold proteins, Adhesion proteins, Calcium-binding proteins, Cell Cycle Regulation or Channel proteins, Chaperones, Cofactor proteins, Cytoskeletal proteins, DNA Binding proteins, G protein or GTPase Activating proteins, Ligases, Lipid Kinases and Binding proteins, Oxidoreductases, Protein Kinases, Protein Phosphatases, Receptor proteins, RNA Binding proteins, Transcription Factor/Initiation Complex proteins, Transcription Coactivator/Corepressor proteins, Translation Initiation Complex proteins, Ubitquitin Conjugating System proteins, and Vesicle proteins.

US Patent:

7939636, May 10, 2011

Filed:

Aug 11, 2006

Appl. No.:

11/503335

Inventors:

Albrecht Moritz - Salem MA, US
Kimberly Lee - Seattle WA, US
John Rush - Beverly MA, US
Roberto Polakiewicz - Lexington MA, US

Assignee:

Cell Signaling Technology, Inc. - Danver MA

International Classification:

G07K 16/00
G07K 16/18

US Classification:

5303871, 5303879

Abstract:

The invention discloses 102 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of c-Src kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Actin Binding proteins, Cytoskeletal proteins, G protein/GTPase Activating protein/Guanine Nucleotide Exchange Factor proteins, Helicases, RNA Binding proteins, Transcription/Translation Factor or Initiation Complex proteins, Cellular Metabolism Enzymes, and Vesicle proteins.

US Patent:

7973134, Jul 5, 2011

Filed:

Aug 11, 2006

Appl. No.:

11/503096

Inventors:

Albrecht Moritz - Salem MA, US
Kimberly Lee - Seattle WA, US
John Rush - Beverly MA, US
Roberto Polakiewicz - Lexington MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C07K 16/00
C07K 16/18

US Classification:

5303871, 5303879

Abstract:

The invention discloses 211 novel phosphorylation sites identified in signal transduction proteins and pathways underlying Anaplastic Large Cell Lymphoma (ALCL) involving the ALK-NPM translocation/fusion, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein Kinases (including Receptor Tyrosine Kinases), Adaptor/Scaffold Proteins, Cellular Metabolism or Miscellaneous Enzymes, Oxidoreductases, Transcription Factors, Cytoskeletal Proteins, Translation Initiation Complexes, RNA Binding Proteins, Proteases, Acetyltransferases, G protein regulators/GTPases, Helicases, Apoptosis/Cell Cycle Regulation proteins, and Hydrolases.

US Patent:

7999080, Aug 16, 2011

Filed:

Jul 13, 2007

Appl. No.:

12/309310

Inventors:

Peter Hornbeck - Magnolia MA, US
Valerie Goss - Seabrook NH, US
Kimberly Lee - Seattle WA, US
Albrecht Moritz - Salem MA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

C07K 16/18

US Classification:

5303879

Abstract:

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

US Patent:

8466160, Jun 18, 2013

Filed:

Dec 30, 2010

Appl. No.:

12/982490

Inventors:

Klarisa Rikova - Reading MA, US
Roberto Polakiewicz - Lexington MA, US
Ailan Guo - Lexington MA, US
Katherine Eleanor Crosby - Middleton MA, US
Qingfu Zeng - Hamilton MA, US
Kimberly A Lee - Seattle WA, US

Assignee:

Cell Signaling Technology, Inc. - Danvers MA

International Classification:

A01N 43/54
G01N 33/574
C12Q 1/68

US Classification:

514256, 435 723, 435 614, 514247

Abstract:

The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFRα) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFRα is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFRα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFRα is expressed, and for determining whether a compound inhibits the progression of a PDGFRα-expressing mammalian NSCLC tumor.